Results 91 to 100 of about 21,171,014 (388)

A child with acquired haemophilia

Ceylon Medical Journal, 2014
Acquired haemophilia A (AHA) is a rare bleeding disorder with high morbidity and mortality due to development of autoantibodies against coagulation factor VIII (FVIII). AHA is frequently seen in elderly and the incidence is approximately 1 case/ million/ year [1]. The incidence in children under age 16 is 0.045/ million/ year [1]. It is associated with
P D, Somaratne, J, Jansan, H M, Senanayake, V, Ratnamalala, M M, Jayathilake, K, Thirumavalavan   +5 more
openaire   +3 more sources

Optimization of CEST MRI Reporter Protein Design Using Cation‐Pi Networks

Chemistry – A European Journal, EarlyView.
A novel engineering approach can produce reporter proteins for cell and viral therapy tracking with unique magnetic resonance imaging (MRI) signatures, detectable with chemical exchange saturation transfer (CEST). We discover how cation‐π interactions between amino acid groups can help us fine‐tune magnetic resonance properties for noninvasive ...
David E. Korenchan, Ethan J. French, Emerenziana Runco, Chetan B. Dhakan, Jinwu Yan, Hiroshi Nakashima, Michael T. McMahon, Assaf A. Gilad, Christian T. Farrar   +8 more
wiley   +1 more source

Evolution of congenital haemophilia care in Taiwan

Journal of the Formosan Medical Association, 2022
Haemophilia care in Taiwan has come a long way over the past 35 years, from the absence of specialised haemophilia treatment centres before 1984 to the establishment of treatment centers in the majority of medical centers, the listing of haemophilia as a
Yeu-Chin Chen, Chia-Yau Chang, Shin-Nan Cheng, Ru-Yu Pan, Yu-Lueng Shih, Tsung-Ying Li, Sheng-Hao Wang   +6 more
doaj   +1 more source

A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]

, 2015
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H., Ahmadinejad, M., Baghaeipour, M.R., Dehdezi, B.K., Eshghi, P., Faranoush, M., Fayazfar, R., Heshmat, R., Hoorfar, H., Kamyar, K., Karimi, M., Khoeiny, B., Managhchi, M., Mehrvar, A., Mirbehbahani, N.B., Naderi, M., Toogeh, G.   +16 more
core  

A new paradigm evaluating cost per cure of HCV infection in the UK [PDF]

, 2016
Background: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with regard to costs and ...
Aline Gauthier, Elizabeth Holtham, Graham S. Cooke, Jeremie Schwarzbard, null null, Petar Atanasov, Stephen T. Barclay, William L. Irving   +7 more
core   +2 more sources

Cost‐effectiveness of fenfluramine as add‐on treatment in the management of Dravet Syndrome: A real‐world multicenter study

Epilepsia Open, EarlyView.
Abstract Objective Dravet syndrome (DS) is a rare disease with a high clinical and socioeconomic impact on patients, society, and the healthcare system. The recent approval of therapies such as fenfluramine (FFA) has transformed the treatment landscape; however, data on their cost‐effectiveness are still scarce. This study evaluates the real‐world cost‐
Paolo A. Cortesi, Carla Fornari, Alessandra Boncristiano, Rita Facchetti, Simona Balestrini, Viola Doccini, Nicola Specchio, Nicola Pietrafusa, Marina Trivisano, Francesca Darra, Alberto Cossu, Domenica I. Battaglia, Michela Quintiliani, Maria L. Gambardella, Lorenzo G. Mantovani, Renzo Guerrini   +15 more
wiley   +1 more source

The impact of severe haemophilia and the presence of target joints on health-related quality-of-life

Health and Quality of Life Outcomes, 2018
Background Joint damage remains a major complication associated with haemophilia and is widely accepted as one of the most debilitating symptoms for persons with severe haemophilia.
Jamie O’Hara, Shaun Walsh, Charlotte Camp, Giuseppe Mazza, Liz Carroll, Christina Hoxer, Lars Wilkinson   +6 more
doaj   +1 more source

Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A. [PDF]

, 2020
Hemophilia A (HA) is a bleeding disorder characterized by spontaneous and prolonged hemorrhage. The disease is caused by mutations in the coagulation factor 8 gene (F8) leading to factor VIII (FVIII) deficiency.
Agu, Emmanuel, Conroy, Kelsey, Cortez-Toledo, Elizabeth, Gao, Kewa, Hyllen, Alicia A, Nolta, Jan A, Pan, Guangjin, Rose, Melanie, Wang, Aijun, Zhou, Ping   +9 more
core   +1 more source

Human parvovirus B19 and blood product safety. A tale of twenty years of improvements [PDF]

, 2015
Parvovirus B19 (B19V), long known to be the causative agent of erythema infectiosum (fifth disease), is not a newly emerging agent. The aim of this review is to analyse the role played by this virus in compromising safety in transfusion medicine and the ...
Calizzani, Gabriele, Candura, Fabio, Facco, Giuseppina, Grazzini, Giuliano, Liumbruno, Giancarlo M., Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +7 more
core   +1 more source

How to discuss gene therapy for haemophilia? A patient and physician perspective

Haemophilia, 2019
Gene therapy has the potential to revolutionise treatment for patients with haemophilia and is close to entering clinical practice. While factor concentrates have improved outcomes, individuals still face a lifetime of injections, pain, progressive joint
Wolfgang A. Miesbach, B. O’Mahony, N. Key, M. Makris   +3 more
semanticscholar   +1 more source